BIIB vs NAGE · P/E 21, rev $9.89B vs P/E 59, rev $61.3M
Biogen Inc (BIIB) versus Niagen Bioscience, Inc. (NAGE) — a side-by-side from cached financials, not a winner call.
Biogen Inc (BIIB) is a drug manufacturers - general company listed on NASDAQ. It is led by Christopher A. Viehbacher.
Niagen Bioscience, Inc. (NAGE) is a biotechnology company listed on US.
Latest reported BIIB revenue for 2025-12-31 was $9.89B. Net income was $1.29B. Revenue was up 2.2% from 2024-12-31 to 2025-12-31. BIIB currently screens at market cap $29.33B and trailing P/E 21.4.
Latest reported NAGE revenue for 2026-06-30 was $61.3M. Net income was $7.3M. Revenue was up 94.6% from 2026-03-31 to 2026-06-30. NAGE currently screens at market cap $836.5M and trailing P/E 59.0.
BIIB currently screens at market cap $29.33B and trailing P/E 21.4. NAGE currently screens at market cap $836.5M and trailing P/E 59.0.
Not investment advice. Open the BIIB and NAGE stock pages for the full models.
Not investment advice.